(Q37381766)

20 August 2017

1 reference

title

Implications of insulin-like growth factor-I for prostate cancer therapies (English)

1 reference

20 August 2017

1 reference

1 reference

Satoko Kojima

1

1 reference

20 August 2017

Masahiko Inahara

2

1 reference

20 August 2017

Hiroyoshi Suzuki

3

1 reference

20 August 2017

Tomohiko Ichikawa

4

1 reference

20 August 2017

Yuzo Furuya

5

1 reference

20 August 2017

publication date

5 December 2008

1 reference

International Journal of Urology

20 August 2017

published in

1 reference

20 August 2017

volume

16

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

161-167

1 reference

Insulin-Like Growth Factor (IGF) family and prostate cancer

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin-like growth factors and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells*

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Serum insulin-like growth factor-I and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Does the GH-IGF axis play a role in cancer pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The role of the IGF system in cancer growth and metastasis: overview and recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The insulin-like growth factor system as a treatment target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The IGF system and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Molecular genetics of human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The role of testosterone in the pathogenesis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The IGF axis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Insulin-Like Growth Factor I (IGF-I) and IGF Binding Protein-1 Modulate Prostate Cancer Cell Growth and Apoptosis: Possible Mediators for the Effects of Diet and Exercise on Cancer Cell Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Therapeutic options in androgen-independent prostate cancer: building on docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Androgen receptor signaling in androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Interaction of IGF signaling and the androgen receptor in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Antagonists of growth hormone-releasing hormone in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

The role of endogenous growth hormone-releasing hormone in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Antisense therapy for cancer--the time of truth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Novel insights into the implication of the IGF-1 network in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Facteurs de risque génétiques pour le cancer de la prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02224.X

10.1111/J.1442-2042.2008.02224.X

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference